Suppr超能文献

采用液相色谱-串联质谱法对人血浆中的索拉非尼及其活性代谢物索拉非尼 N-氧化物进行定量分析。

Quantitation of sorafenib and its active metabolite sorafenib N-oxide in human plasma by liquid chromatography-tandem mass spectrometry.

机构信息

Department of Pharmaceutical Sciences, St. Jude Children's Research Hospital, Memphis, TN 38105, USA.

出版信息

J Chromatogr B Analyt Technol Biomed Life Sci. 2010 Nov 1;878(29):3033-8. doi: 10.1016/j.jchromb.2010.08.049. Epub 2010 Sep 9.

Abstract

A simple and rapid method with high performance liquid chromatography/tandem mass spectrometry is described for the quantitation of the kinase inhibitor sorafenib and its active metabolite sorafenib N-oxide in human plasma. A protein precipitation extraction procedure was applied to 50 μL of plasma. Chromatographic separation of the two analytes, and the internal standard [(2)H(3)(13)C]-sorafenib, was achieved on a C(18) analytical column and isocratic flow at 0.3 mL/min for 4 min. Mean within-run and between-run precision for all analytes were <6.9% and accuracy was <5.3%. Calibration curves were linear over the concentration range of 50-10,000 ng/mL for sorafenib and 10-2500 ng/mL for sorafenib N-oxide. This method allows a specific, sensitive, and reliable determination of the kinase inhibitor sorafenib and its active metabolite sorafenib N-oxide in human plasma in a single analytical run.

摘要

一种简单、快速、高效液相色谱/串联质谱法用于定量检测人血浆中的激酶抑制剂索拉非尼及其活性代谢物索拉非尼 N-氧化物。采用蛋白沉淀提取法处理 50μL 血浆。两种分析物和内标[(2)H(3)(13)C]-索拉非尼在 C(18)分析柱上以 0.3mL/min 的等度流速在 4min 内实现色谱分离。所有分析物的日内和日间精密度均<6.9%,准确度均<5.3%。索拉非尼的浓度范围为 50-10000ng/mL,索拉非尼 N-氧化物的浓度范围为 10-2500ng/mL,校准曲线在此范围内呈线性。该方法可在单次分析运行中特异性、灵敏、可靠地测定人血浆中的激酶抑制剂索拉非尼及其活性代谢物索拉非尼 N-氧化物。

相似文献

1
Quantitation of sorafenib and its active metabolite sorafenib N-oxide in human plasma by liquid chromatography-tandem mass spectrometry.
J Chromatogr B Analyt Technol Biomed Life Sci. 2010 Nov 1;878(29):3033-8. doi: 10.1016/j.jchromb.2010.08.049. Epub 2010 Sep 9.
2
A rapid and sensitive method for determination of sorafenib in human plasma using a liquid chromatography/tandem mass spectrometry assay.
J Chromatogr B Analyt Technol Biomed Life Sci. 2007 Feb 1;846(1-2):1-7. doi: 10.1016/j.jchromb.2006.06.005. Epub 2006 Jun 23.
3
Development of a rapid and sensitive LC-MS/MS assay for the determination of sorafenib in human plasma.
J Pharm Biomed Anal. 2008 Jan 22;46(2):362-7. doi: 10.1016/j.jpba.2007.10.027.
6
Therapeutic Drug Monitoring of the new targeted anticancer agents imatinib, nilotinib, dasatinib, sunitinib, sorafenib and lapatinib by LC tandem mass spectrometry.
J Chromatogr B Analyt Technol Biomed Life Sci. 2009 Jul 15;877(22):1982-96. doi: 10.1016/j.jchromb.2009.04.045. Epub 2009 May 13.
7
Liquid chromatography-tandem mass spectrometric assay for sorafenib and sorafenib-glucuronide in mouse plasma and liver homogenate and identification of the glucuronide metabolite.
J Chromatogr B Analyt Technol Biomed Life Sci. 2009 Jan 15;877(3):269-76. doi: 10.1016/j.jchromb.2008.12.026. Epub 2008 Dec 24.
8
The plasma and cerebrospinal fluid pharmacokinetics of sorafenib after intravenous administration in non-human primates.
Invest New Drugs. 2012 Apr;30(2):524-8. doi: 10.1007/s10637-010-9585-1. Epub 2010 Nov 12.

引用本文的文献

3
Targeting aberrant replication and DNA repair events for treating breast cancers.
Commun Biol. 2022 May 24;5(1):493. doi: 10.1038/s42003-022-03413-w.
4
Influence of Probenecid on the Pharmacokinetics and Pharmacodynamics of Sorafenib.
Pharmaceutics. 2020 Aug 20;12(9):788. doi: 10.3390/pharmaceutics12090788.
6
A Prospective Study of Peritransplant Sorafenib for Patients with FLT3-ITD Acute Myeloid Leukemia Undergoing Allogeneic Transplantation.
Biol Blood Marrow Transplant. 2020 Feb;26(2):300-306. doi: 10.1016/j.bbmt.2019.09.023. Epub 2019 Sep 21.
8
Development and validation of an analytical method for regorafenib and its metabolites in mouse plasma.
J Chromatogr B Analyt Technol Biomed Life Sci. 2018 Jul 15;1090:43-51. doi: 10.1016/j.jchromb.2018.05.005. Epub 2018 May 5.
9
Sorafenib Dose Recommendation in Acute Myeloid Leukemia Based on Exposure-FLT3 Relationship.
Clin Transl Sci. 2018 Jul;11(4):435-443. doi: 10.1111/cts.12555. Epub 2018 Apr 27.
10
Sorafenib improves alkylating therapy by blocking induced inflammation, invasion and angiogenesis in breast cancer cells.
Cancer Lett. 2018 Jul 1;425:101-115. doi: 10.1016/j.canlet.2018.03.037. Epub 2018 Mar 30.

本文引用的文献

1
Therapeutic Drug Monitoring of the new targeted anticancer agents imatinib, nilotinib, dasatinib, sunitinib, sorafenib and lapatinib by LC tandem mass spectrometry.
J Chromatogr B Analyt Technol Biomed Life Sci. 2009 Jul 15;877(22):1982-96. doi: 10.1016/j.jchromb.2009.04.045. Epub 2009 May 13.
2
Validation of an HPLC-UV method for sorafenib determination in human plasma and application to cancer patients in routine clinical practice.
J Pharm Biomed Anal. 2009 May 1;49(4):1109-14. doi: 10.1016/j.jpba.2009.02.008. Epub 2009 Feb 20.
3
Sorafenib: a review of its use in advanced hepatocellular carcinoma.
Drugs. 2009;69(2):223-40. doi: 10.2165/00003495-200969020-00006.
4
Potential role of sorafenib in the treatment of acute myeloid leukemia.
Leuk Lymphoma. 2008 Dec;49(12):2246-55. doi: 10.1080/10428190802510349.
5
Development of a rapid and sensitive LC-MS/MS assay for the determination of sorafenib in human plasma.
J Pharm Biomed Anal. 2008 Jan 22;46(2):362-7. doi: 10.1016/j.jpba.2007.10.027.
6
Discovery and development of sorafenib: a multikinase inhibitor for treating cancer.
Nat Rev Drug Discov. 2006 Oct;5(10):835-44. doi: 10.1038/nrd2130.
7
A rapid and sensitive method for determination of sorafenib in human plasma using a liquid chromatography/tandem mass spectrometry assay.
J Chromatogr B Analyt Technol Biomed Life Sci. 2007 Feb 1;846(1-2):1-7. doi: 10.1016/j.jchromb.2006.06.005. Epub 2006 Jun 23.
8
Lack of effect of ketoconazole-mediated CYP3A inhibition on sorafenib clinical pharmacokinetics.
Cancer Chemother Pharmacol. 2006 May;57(5):685-92. doi: 10.1007/s00280-005-0068-6. Epub 2005 Aug 25.
9
Factors affecting cytochrome P-450 3A activity in cancer patients.
Clin Cancer Res. 2004 Dec 15;10(24):8341-50. doi: 10.1158/1078-0432.CCR-04-1371.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验